ST上昇型急性心筋梗塞の診療に関するガイドライン（2013年改訂版）
Guidelines for the management of patients with ST-elevation acute myocardial infarction
（JCS 2013）
文献
401. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010
ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
Eur Heart J 2012; 33: 2719-2747.
402. 日本透析医学会．血液透析患者における心血管合併症の評価と治療に関するガイドライン．透析会誌 2011; 44: 337-425.
403. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;
344: 1383-1389.
404. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol
levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
405. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
406. Sakamoto T, Kojima S, Ogawa H, et al. Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With
Acute Myocardial Infarction Investigators. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial
infarction in Japanese. Am J Cardiol 2006; 97: 1165-1171.
407. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on
atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation
2004; 110: 1061-1068.
408. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary
syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54: 293-302.
409. Dohi T, Miyauchi K, Okazaki S, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute
coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis 2010; 210: 497-502.
410. O’Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll
Cardiol 2004; 43: 2142-2146.
411. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment:
prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
412. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187-1192.
413. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-
1331.
414. Ishihara M, Kojima S, Sakamoto T, et al. Japanese Acute Coronary Syndrome Study Investigators. Acute hyperglycemia is associated with adverse
outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 2005; 150: 814-820.
415. Ishihara M. Acute hyperglycemia in patients with acute myocardial infarction. Circ J 2012; 76: 563-571.
416. Kosuge M, Kimura K, Ishikawa T, et al. Persistent hyperglycemia is associated with left ventricular dysfunction in patients with acute myocardial
infarction. Circ J 2005; 69: 23-28.
417. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients
with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
418. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulinpotassium infusion on mortality in patients with acute ST-segment elevation myocardial
infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-446.
419. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med
2004; 164: 2005-2011.
420. Svensson AM, McGuire DK, Abrahamsson P, et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic
patients with acute coronary events. Eur Heart J 2005; 26: 1255-1261.
421. Chiriboga D, Yarzebski J, Goldberg RJ, et al. Temporal trends (1975 through 1990) in the incidence and case-fatality rates of primary ventricular
fibrillation complicating acute myocardial infarction. A communitywide perspective. Circulation 1994; 89: 998-1003.
422. Campbell RW, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br Heart J 1981; 46:
351-357.
423. O’Doherty M, Tayler DI, Quinn E, et al. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J (Clin Res
Ed) 1983; 286: 1405-1408.
424. Lie KI, Wellens HJ, Downar E, et al. Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation
1975; 52: 755-759.
425. Pantridge JF, Geddes JS. A mobile intensive-care unit in the management of myocardial infarction. Lancet 1967; 2: 271-273.
426. Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol
1997; 79: 1512-1516.
427. Colquhoun MC, Julien DG. Sudden death in the community - the arrhythmiacausing cardiac arrest and results of immediate resuscitation.
Resuscitation 1992; 24: 177A.
428. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA
study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur Heart J 2000; 21: 198-205.
429. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997;
80: 35J-39J.
430. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S729-767.
431. Ando J, Kakishita M, Sakai K, et al. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart
disease. Int Heart J 2005; 46: 647-656.
432. Katoh T, Mitamura H, Matsuda N, et al. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for lifethreatening refractory
ventricular tachyarrhythmias: post-marketing special investigation. Circ J 2005; 69: 1237-1243.
433. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346: 884-
890.
434. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med
1999; 341: 871-878.
435. Shiga T, Tanaka K, Kato R, et al. Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study
Investigators. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. Resuscitation 2010; 81: 47-52.
436. Tahara Y, Kimura K, Kosuge M, et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J 2006;
70: 442-446.
437. Kagawa E, Dote K, Kato M, et al. Should we emergently revascularize occluded coronaries for cardiac arrest?: rapidresponse extracorporeal
membrane oxygenation and intra-arrest percutaneous coronary intervention. Circulation 2012; 126: 1605-1613.
438. Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84: 1543-
1551.
439. Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart
failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial
Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22: 1773-1779.
440. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention
of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of
Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
Circulation 2006; 114: e385-484.
441. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular
tachycardia. Am J Cardiol 2002; 90: 853-859.
442. Marill KA, deSouza IS, Nishijima DK, et al. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med 2006;
47: 217-224.
443. Schutzenberger W, Leisch F, Kerschner K, et al. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained
ventricular tachycardia and ventricular fibrillation. Br Heart J 1989; 62: 367-371.
444. Tomlinson DR, Cherian P, Betts TR, et al. Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained
ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment? Emerg Med J 2008; 25: 15-18.
445. Yusu S, Ikeda T, Mera H, et al. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute
coronary syndrome. Circ J 2009; 73: 2021-2028.
446. Nademanee K, Taylor RD, Bailey WM. Management and longterm outcome of patients with electrical storm. J Am Coll Cardiol 1995; 25: 187A.
447. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life supportguided therapy.
Circulation 2000; 102: 742-747.
448. Miwa Y, Ikeda T, Mera H, et al. Effects of landiolol, an ultra-shortacting beta1-selective blocker, on electrical storm refractory to class III
antiarrhythmic drugs. Circ J 2010; 74: 856-863.
449. Kurisu S, Inoue I, Kawagoe T, et al. Temporary overdriving pacing as an adjunct to antiarrhythmic drug therapy for electrical storm in acute
myocardial infarction. Circ J 2005; 69: 613-616.
450. Bansch D, Oyang F, Antz M, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003; 108: 3011-3016.
451. Nordrehaug JE, Johannessen KA, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute
myocardial infarction. Circulation 1985; 71: 645-649.
452. Shea S, Bigger JT, Campion J, et al. Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial
(CAST). Control Clin Trials 1992; 13: 466-486.
453. Lie KI, Wellens HJ, Durrer D. Characteristics and predictability of primary ventricular fibrillation. Eur J Cardiol 1974; 1: 379-384.
454. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes.
Circulation 2000; 101: 969-974.
455. Pedersen OD, Bagger H, Kober L, et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction.
TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20: 748-754.
456. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization
of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 406-413.
457. Camm AJ, Capucci A, Hohnloser SH, et al. AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of
vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57: 313-321.
458. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure
and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department
of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574-2579.
459. Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias.
Am J Cardiol 1998; 81: 594-598.
460. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the
management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on
practice guidelines. Circulation 2011; 123: e269-367.
461. Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β 1-adrenergic blocker, in
patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2012; 76: 439-445.
462. Moss AJ, Oakes D, Benhorin J, et al. The interaction between diltiazem and left ventricular function after myocardial infarction. Multicenter Diltiazem
Post-Infarction Research Group. Circulation 1989; 80: IV102-106.
463. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct
Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530.
464. Wenzel V, Krismer AC, Arntz HR, et al. European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group. A
comparison of vasopressin and epinephrine for out-ofhospital cardiopulmonary resuscitation. N Engl J Med 2004; 350: 105-113.
465. Coon GA, Clinton JE, Ruiz E. Use of atropine for brady-asystolic prehospital cardiac arrest. Ann Emerg Med 1981; 10: 462-467.
466. Tortolani AJ, Risucci DA, Powell SR, et al. In-hospital cardiopulmonary resuscitation during asystole. Therapeutic factors associated with 24-hour
survival. Chest 1989; 96: 622-626.
467. Engdahl J, Bang A, Lindqvist J, et al. Can we define patients with no and those with some chance of survival when found in asystole out of hospital?
Am J Cardiol 2000; 86: 610-614.
468. Survey of Survivors After Out-of-hospital Cardiac Arrest in KANTO Area JpS-KSG. Atropine sulfate for patients with out-ofhospital cardiac arrest due to
asystole and pulseless electrical activity. Circ J 2011; 75: 580-588.
469. 日本蘇生協議会ガイドライン2010．成人の二次救命処置（2010年改訂版）．http://www.qqzaidan.jp/pdf_5/guideline2_ALS_kakutei.pdf（2012年11月閲覧）
470. Kimura K, Kosuge M, Ishikawa T, et al. Comparison of results of early reperfusion in patients with inferior wall acute myocardial infarction with and
without complete atrioventricular block. Am J Cardiol 1999; 84: 731-733, A738.
471. Barthell E, Troiano P, Olson D, et al. Prehospital external cardiac pacing: a prospective, controlled clinical trial. Ann Emerg Med 1988; 17: 1221-1226.
472. Cummins RO, Graves JR, Larsen MP, et al. Out-of-hospital transcutaneous pacing by emergency medical technicians in patients with asystolic
cardiac arrest. N Engl J Med 1993; 328: 1377-1382.
473. White JD, Brown CG. Immediate transthoracic pacing for cardiac asystole in an emergency department setting. Am J Emerg Med 1985; 3: 125-128.
474. Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction 2. Indications for
temporary and permanent pacemaker insertion. Circulation 1978; 58: 689-699.
475. 循環器病の診断と治療に関するガイドライン．不整脈の非薬物治療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011
_okumura_h.pdf
476. Colucci WS, Braunwald E. Pathology of heart failure. In: Braunwald E, editor. Heart Disease, 5th edn. Saunders, 1997; 394-420.
477. Page DL, Caulfield JB, Kastor JA, et al. Myocardial changes associated with cardiogenic shock. N Engl J Med 1971; 285: 133-137.
478. Werns SW, Bates ER. The enduring value of Killip classification. Am Heart J 1999; 137: 213-215.
479. Rott D, Behar S, Gottlieb S, et al. Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the
1990s compared with those treated in the 1980s. Israeli Thrombolytic Survey Group and the Secondary Prevention Reinfarction Israeli Nifedipine
Trial (SPRINT) Study Group. Am J Cardiol 1997; 80: 859-864.
480. 三浦俊郎，松崎益徳．ベッドサイドでの心機能と心不全重症度の評価．日内会誌 1994; 83: 31-36.
481. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol
1977; 39: 137-145.
482. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart
failure. J Am Coll Cardiol 2003; 41: 1797-1804.
483. 循環器病の診断と治療に関するガイドライン．急性心不全治療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011_izumi_h.pdf
（2012年12月閲覧）
484. Mueller HS, Chatterjee K, Davis KB, et al. ACC expert consensus document. Present use of bedside right heart catheterization in patients with
cardiac disease. American College of Cardiology. J Am Coll Cardiol 1998; 32: 840-864.
485. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control
and Prevention. MMWR Recomm Rep 2002; 51: 1-29.
486. Hochman JS, Jaber WA, Bates ER, et al. Angioplasty versus thrombolytics for patients presenting with congestive heart failure: GUSTO IIb substudy
findings. J Am Coll Cardiol 1998; 31: 210-211.
487. DeGeare VS, Boura JA, Grines LL, et al. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention
for acute myocardial infarction. Am J Cardiol 2001; 87: 1035-1038.
488. Bersten AD, Holt AW, Vedig AE, et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face
mask. N Engl J Med 1991; 325: 1825-1830.
489. Takeda S, Nejima J, Takano T, et al. Effect of nasal continuous positive airway pressure on pulmonary edema complicating acute myocardial
infarction. Jpn Circ J 1998; 62: 553-558.
490. Masip J, Betbese AJ, Paez J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary
oedema: a randomised trial. Lancet 2000; 356: 2126-2132.
491. 田中啓治．急性心不全の治療：呼吸管理の実際．心臓 2011; 43: 432-435.
492. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7: the era of reperfusion: section 1: acute coronary
syndromes (acute myocardial infarction). The American Heart Association in collaboration with the International Liaison Committee on Resuscitation.
Circulation 2000; 102: I172-203.
493. Zelis R, Kinney EL, Flaim SF, et al. Morphine: Its use in pulmonary edema. Cardiovasc Rev Rep 1981; 2: 257-267.
494. Semba H, Kinugawa K, Takeda N, et al. Preliminary report of tolvaptan treatment in Japanese patients with heart failure. Int Heart J 2012; 53: 72-74.
495. Kikuchi M, Nakamura M, Suzuki T, et al. Usefulness of carperitide for the treatment of refractory heart failure due to severe acute myocardial infarction.
Jpn Heart J 2001; 42: 271-280.
496. 横山広行．腎機能障害を伴う急性心不全に対する心房性ナトリウム利尿ペプチドの効果．心臓 2004; 36: 61-65.
497. Asakura M, Jiyoong K, Minamino T, et al. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to
percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the
reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 2004; 68: 95-100.
498. Stone GW, Marsalese D, Brodie BR, et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk
patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial
Investigators. J Am Coll Cardiol 1997; 29: 1459-1467.
499. Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK
trial registry. Am J Med 2000; 108: 374-380.
500. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction―etiologies, management and outcome: a
report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:
1063-1070.
ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
Eur Heart J 2012; 33: 2719-2747.
402. 日本透析医学会．血液透析患者における心血管合併症の評価と治療に関するガイドライン．透析会誌 2011; 44: 337-425.
403. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;
344: 1383-1389.
404. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol
levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
405. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
406. Sakamoto T, Kojima S, Ogawa H, et al. Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With
Acute Myocardial Infarction Investigators. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial
infarction in Japanese. Am J Cardiol 2006; 97: 1165-1171.
407. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on
atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation
2004; 110: 1061-1068.
408. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary
syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54: 293-302.
409. Dohi T, Miyauchi K, Okazaki S, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute
coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis 2010; 210: 497-502.
410. O’Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll
Cardiol 2004; 43: 2142-2146.
411. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment:
prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
412. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187-1192.
413. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-
1331.
414. Ishihara M, Kojima S, Sakamoto T, et al. Japanese Acute Coronary Syndrome Study Investigators. Acute hyperglycemia is associated with adverse
outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 2005; 150: 814-820.
415. Ishihara M. Acute hyperglycemia in patients with acute myocardial infarction. Circ J 2012; 76: 563-571.
416. Kosuge M, Kimura K, Ishikawa T, et al. Persistent hyperglycemia is associated with left ventricular dysfunction in patients with acute myocardial
infarction. Circ J 2005; 69: 23-28.
417. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients
with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
418. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulinpotassium infusion on mortality in patients with acute ST-segment elevation myocardial
infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-446.
419. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med
2004; 164: 2005-2011.
420. Svensson AM, McGuire DK, Abrahamsson P, et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic
patients with acute coronary events. Eur Heart J 2005; 26: 1255-1261.
421. Chiriboga D, Yarzebski J, Goldberg RJ, et al. Temporal trends (1975 through 1990) in the incidence and case-fatality rates of primary ventricular
fibrillation complicating acute myocardial infarction. A communitywide perspective. Circulation 1994; 89: 998-1003.
422. Campbell RW, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br Heart J 1981; 46:
351-357.
423. O’Doherty M, Tayler DI, Quinn E, et al. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J (Clin Res
Ed) 1983; 286: 1405-1408.
424. Lie KI, Wellens HJ, Downar E, et al. Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation
1975; 52: 755-759.
425. Pantridge JF, Geddes JS. A mobile intensive-care unit in the management of myocardial infarction. Lancet 1967; 2: 271-273.
426. Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol
1997; 79: 1512-1516.
427. Colquhoun MC, Julien DG. Sudden death in the community - the arrhythmiacausing cardiac arrest and results of immediate resuscitation.
Resuscitation 1992; 24: 177A.
428. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA
study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur Heart J 2000; 21: 198-205.
429. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997;
80: 35J-39J.
430. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S729-767.
431. Ando J, Kakishita M, Sakai K, et al. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart
disease. Int Heart J 2005; 46: 647-656.
432. Katoh T, Mitamura H, Matsuda N, et al. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for lifethreatening refractory
ventricular tachyarrhythmias: post-marketing special investigation. Circ J 2005; 69: 1237-1243.
433. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346: 884-
890.
434. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med
1999; 341: 871-878.
435. Shiga T, Tanaka K, Kato R, et al. Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study
Investigators. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. Resuscitation 2010; 81: 47-52.
436. Tahara Y, Kimura K, Kosuge M, et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J 2006;
70: 442-446.
437. Kagawa E, Dote K, Kato M, et al. Should we emergently revascularize occluded coronaries for cardiac arrest?: rapidresponse extracorporeal
membrane oxygenation and intra-arrest percutaneous coronary intervention. Circulation 2012; 126: 1605-1613.
438. Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84: 1543-
1551.
439. Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart
failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial
Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22: 1773-1779.
440. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention
of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of
Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
Circulation 2006; 114: e385-484.
441. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular
tachycardia. Am J Cardiol 2002; 90: 853-859.
442. Marill KA, deSouza IS, Nishijima DK, et al. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med 2006;
47: 217-224.
443. Schutzenberger W, Leisch F, Kerschner K, et al. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained
ventricular tachycardia and ventricular fibrillation. Br Heart J 1989; 62: 367-371.
444. Tomlinson DR, Cherian P, Betts TR, et al. Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained
ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment? Emerg Med J 2008; 25: 15-18.
445. Yusu S, Ikeda T, Mera H, et al. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute
coronary syndrome. Circ J 2009; 73: 2021-2028.
446. Nademanee K, Taylor RD, Bailey WM. Management and longterm outcome of patients with electrical storm. J Am Coll Cardiol 1995; 25: 187A.
447. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life supportguided therapy.
Circulation 2000; 102: 742-747.
448. Miwa Y, Ikeda T, Mera H, et al. Effects of landiolol, an ultra-shortacting beta1-selective blocker, on electrical storm refractory to class III
antiarrhythmic drugs. Circ J 2010; 74: 856-863.
449. Kurisu S, Inoue I, Kawagoe T, et al. Temporary overdriving pacing as an adjunct to antiarrhythmic drug therapy for electrical storm in acute
myocardial infarction. Circ J 2005; 69: 613-616.
450. Bansch D, Oyang F, Antz M, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003; 108: 3011-3016.
451. Nordrehaug JE, Johannessen KA, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute
myocardial infarction. Circulation 1985; 71: 645-649.
452. Shea S, Bigger JT, Campion J, et al. Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial
(CAST). Control Clin Trials 1992; 13: 466-486.
453. Lie KI, Wellens HJ, Durrer D. Characteristics and predictability of primary ventricular fibrillation. Eur J Cardiol 1974; 1: 379-384.
454. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes.
Circulation 2000; 101: 969-974.
455. Pedersen OD, Bagger H, Kober L, et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction.
TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20: 748-754.
456. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization
of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 406-413.
457. Camm AJ, Capucci A, Hohnloser SH, et al. AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of
vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57: 313-321.
458. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure
and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department
of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574-2579.
459. Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias.
Am J Cardiol 1998; 81: 594-598.
460. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the
management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on
practice guidelines. Circulation 2011; 123: e269-367.
461. Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β 1-adrenergic blocker, in
patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2012; 76: 439-445.
462. Moss AJ, Oakes D, Benhorin J, et al. The interaction between diltiazem and left ventricular function after myocardial infarction. Multicenter Diltiazem
Post-Infarction Research Group. Circulation 1989; 80: IV102-106.
463. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct
Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530.
464. Wenzel V, Krismer AC, Arntz HR, et al. European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group. A
comparison of vasopressin and epinephrine for out-ofhospital cardiopulmonary resuscitation. N Engl J Med 2004; 350: 105-113.
465. Coon GA, Clinton JE, Ruiz E. Use of atropine for brady-asystolic prehospital cardiac arrest. Ann Emerg Med 1981; 10: 462-467.
466. Tortolani AJ, Risucci DA, Powell SR, et al. In-hospital cardiopulmonary resuscitation during asystole. Therapeutic factors associated with 24-hour
survival. Chest 1989; 96: 622-626.
467. Engdahl J, Bang A, Lindqvist J, et al. Can we define patients with no and those with some chance of survival when found in asystole out of hospital?
Am J Cardiol 2000; 86: 610-614.
468. Survey of Survivors After Out-of-hospital Cardiac Arrest in KANTO Area JpS-KSG. Atropine sulfate for patients with out-ofhospital cardiac arrest due to
asystole and pulseless electrical activity. Circ J 2011; 75: 580-588.
469. 日本蘇生協議会ガイドライン2010．成人の二次救命処置（2010年改訂版）．http://www.qqzaidan.jp/pdf_5/guideline2_ALS_kakutei.pdf（2012年11月閲覧）
470. Kimura K, Kosuge M, Ishikawa T, et al. Comparison of results of early reperfusion in patients with inferior wall acute myocardial infarction with and
without complete atrioventricular block. Am J Cardiol 1999; 84: 731-733, A738.
471. Barthell E, Troiano P, Olson D, et al. Prehospital external cardiac pacing: a prospective, controlled clinical trial. Ann Emerg Med 1988; 17: 1221-1226.
472. Cummins RO, Graves JR, Larsen MP, et al. Out-of-hospital transcutaneous pacing by emergency medical technicians in patients with asystolic
cardiac arrest. N Engl J Med 1993; 328: 1377-1382.
473. White JD, Brown CG. Immediate transthoracic pacing for cardiac asystole in an emergency department setting. Am J Emerg Med 1985; 3: 125-128.
474. Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction 2. Indications for
temporary and permanent pacemaker insertion. Circulation 1978; 58: 689-699.
475. 循環器病の診断と治療に関するガイドライン．不整脈の非薬物治療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011
_okumura_h.pdf
476. Colucci WS, Braunwald E. Pathology of heart failure. In: Braunwald E, editor. Heart Disease, 5th edn. Saunders, 1997; 394-420.
477. Page DL, Caulfield JB, Kastor JA, et al. Myocardial changes associated with cardiogenic shock. N Engl J Med 1971; 285: 133-137.
478. Werns SW, Bates ER. The enduring value of Killip classification. Am Heart J 1999; 137: 213-215.
479. Rott D, Behar S, Gottlieb S, et al. Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the
1990s compared with those treated in the 1980s. Israeli Thrombolytic Survey Group and the Secondary Prevention Reinfarction Israeli Nifedipine
Trial (SPRINT) Study Group. Am J Cardiol 1997; 80: 859-864.
480. 三浦俊郎，松崎益徳．ベッドサイドでの心機能と心不全重症度の評価．日内会誌 1994; 83: 31-36.
481. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol
1977; 39: 137-145.
482. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart
failure. J Am Coll Cardiol 2003; 41: 1797-1804.
483. 循環器病の診断と治療に関するガイドライン．急性心不全治療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011_izumi_h.pdf
（2012年12月閲覧）
484. Mueller HS, Chatterjee K, Davis KB, et al. ACC expert consensus document. Present use of bedside right heart catheterization in patients with
cardiac disease. American College of Cardiology. J Am Coll Cardiol 1998; 32: 840-864.
485. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control
and Prevention. MMWR Recomm Rep 2002; 51: 1-29.
486. Hochman JS, Jaber WA, Bates ER, et al. Angioplasty versus thrombolytics for patients presenting with congestive heart failure: GUSTO IIb substudy
findings. J Am Coll Cardiol 1998; 31: 210-211.
487. DeGeare VS, Boura JA, Grines LL, et al. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention
for acute myocardial infarction. Am J Cardiol 2001; 87: 1035-1038.
488. Bersten AD, Holt AW, Vedig AE, et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face
mask. N Engl J Med 1991; 325: 1825-1830.
489. Takeda S, Nejima J, Takano T, et al. Effect of nasal continuous positive airway pressure on pulmonary edema complicating acute myocardial
infarction. Jpn Circ J 1998; 62: 553-558.
490. Masip J, Betbese AJ, Paez J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary
oedema: a randomised trial. Lancet 2000; 356: 2126-2132.
491. 田中啓治．急性心不全の治療：呼吸管理の実際．心臓 2011; 43: 432-435.
492. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7: the era of reperfusion: section 1: acute coronary
syndromes (acute myocardial infarction). The American Heart Association in collaboration with the International Liaison Committee on Resuscitation.
Circulation 2000; 102: I172-203.
493. Zelis R, Kinney EL, Flaim SF, et al. Morphine: Its use in pulmonary edema. Cardiovasc Rev Rep 1981; 2: 257-267.
494. Semba H, Kinugawa K, Takeda N, et al. Preliminary report of tolvaptan treatment in Japanese patients with heart failure. Int Heart J 2012; 53: 72-74.
495. Kikuchi M, Nakamura M, Suzuki T, et al. Usefulness of carperitide for the treatment of refractory heart failure due to severe acute myocardial infarction.
Jpn Heart J 2001; 42: 271-280.
496. 横山広行．腎機能障害を伴う急性心不全に対する心房性ナトリウム利尿ペプチドの効果．心臓 2004; 36: 61-65.
497. Asakura M, Jiyoong K, Minamino T, et al. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to
percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the
reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 2004; 68: 95-100.
498. Stone GW, Marsalese D, Brodie BR, et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk
patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial
Investigators. J Am Coll Cardiol 1997; 29: 1459-1467.
499. Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK
trial registry. Am J Med 2000; 108: 374-380.
500. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction―etiologies, management and outcome: a
report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:
1063-1070.